Nice Systems Ltd (NICE.TA)

NICE.TA on Tel Aviv Stock Exchange

14,950.00
10:24am EDT
Price Change (% chg)

-40.00₪ (-0.27%)
Prev Close
14,990.00₪
Open
15,100.00₪
Day's High
15,170.00₪
Day's Low
14,950.00₪
Volume
63,328
Avg. Vol
82,621
52-wk High
15,870.00₪
52-wk Low
13,060.00₪

NICE.TA

Chart for NICE.TA

About

Nice Systems Ltd (NICE) is a provider of solutions that enable enterprises and security organizations to extract insight from interactions, transactions and surveillance. Its solutions enable companies and public organizations to capture, manage, analyze and impact unstructured interaction, as well as transactional data,... (more)

Overall

Beta: 0.83
Market Cap (Mil.): ₪9,054.59
Shares Outstanding (Mil.): 60.30
Dividend: 55.74
Yield (%): 1.49

Financials

  NICE.TA Industry Sector
P/E (TTM): 52.90 30.71 16.37
EPS (TTM): 2.84 -- --
ROI: 4.20 18.48 16.90
ROE: 4.38 20.43 17.50
Search Stocks

UK cost agency NICE rejects another Roche cancer drug

LONDON - Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.

02 Oct 2014

UK cost agency NICE rejects another Roche cancer drug

LONDON, Oct 3 - Another new cancer drug from Roche , this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.

02 Oct 2014

GSK melanoma pill backed by UK cost watchdog with price cut

LONDON - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service.

17 Sep 2014

GSK melanoma pill backed by UK cost watchdog with price cut

LONDON, Sept 18 - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service.

17 Sep 2014

Israel's Nice Systems Q2 profit falls, revenue up

TEL AVIV, July 30 - Israeli software provider Nice Systems posted lower second-quarter net profit that missed analysts' estimates by two cents and maintained its full year outlook.

30 Jul 2014

BRIEF-Nokia buys 3D geolocation capabilities from Nice Systems

HELSINKI, July 3 - Nokia Oyj : * Says buys 3d geolocation capabilities from Nice Systems Ltd (Reporting by Helsinki Newsroom)

03 Jul 2014

UK body blocks earlier use of J&J prostate cancer drug

LONDON - Britain's healthcare cost-effectiveness agency NICE said on Wednesday that a Johnson & Johnson prostate cancer drug, originally invented in Britain, was not worth giving to patients who have yet to receive chemotherapy.

13 May 2014

UK body blocks earlier use of J&J prostate cancer drug

LONDON, May 14 - Britain's healthcare cost-effectiveness agency NICE said on Wednesday that a Johnson & Johnson prostate cancer drug, originally invented in Britain, was not worth giving to patients who have yet to receive chemotherapy.

13 May 2014

UPDATE 1-Nice Systems cuts 2014 profit and revenue forecasts

* Cuts 2014 rev range to $995 mln-$1.025 bln, EPS ex-items to $2.68-$2.80

08 May 2014

BRIEF-Nice Systems CEO says will be aggressive on acquisitions

May 8 - Nice Systems's Chief Executive Officer Barak Eilam said:

08 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks